跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,939 条关于
“MyD88 mutations”
全部
5,939
临床试验
3,149
药物
26
机构
3
资讯
2,761
去年
SPIMA Therapeutics Launches with Exclusive License for Myddosome Inhibitor SPM001
去年
Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise
去年
SPIMA Therapeutics Launches with Focus on Peptide-Based Immunotherapies for Unmet Needs
去年
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in Waldenstrom's Macroglobulinemia
去年
NX-5948 Demonstrates Promising Activity in Relapsed/Refractory Waldenström Macroglobulinemia
去年
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
2年前
Sanofi's KT-474 Shows Promise as First-in-Class MyD88 Inhibitor for Inflammatory Diseases
11个月前
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
9天前
Waldenström Macroglobulinemia Market Poised for Steady Growth Through 2036 on Novel BTK Degraders, Non-Covalent BTKis, and Targeted Radiotherapeutics
去年
Immunotherapy Strategies Evolving for NSCLC with KRAS and STK11 Mutations
第 1 页,共 277 页
上一页
下一页